Zacks: Analysts Set $26.75 Target Price for Takeda Pharmaceutical Co Ltd (NYSE:TAK)

Takeda Pharmaceutical Co Ltd (NYSE:TAK) has been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price objective of $26.75 for the company, according to Zacks. Zacks has also given Takeda Pharmaceutical an industry rank of 82 out of 256 based on the ratings given to its competitors.

A number of research analysts recently issued reports on TAK shares. Zacks Investment Research upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research note on Wednesday, March 13th. Goldman Sachs Group reiterated a “buy” rating on shares of Takeda Pharmaceutical in a research note on Tuesday, March 19th. Finally, ValuEngine downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th.

Takeda Pharmaceutical stock traded down $0.26 during trading on Friday, reaching $17.09. The stock had a trading volume of 1,020,879 shares, compared to its average volume of 1,882,595. Takeda Pharmaceutical has a 52-week low of $15.50 and a 52-week high of $21.95. The company has a quick ratio of 0.82, a current ratio of 1.22 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $26.70 billion, a P/E ratio of 33.51 and a beta of 0.69.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Tuesday, May 14th. The company reported $0.13 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 10.60% and a return on equity of 12.18%. The company had revenue of $3.51 billion during the quarter. As a group, research analysts anticipate that Takeda Pharmaceutical will post -0.89 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of TAK. First Hawaiian Bank acquired a new stake in Takeda Pharmaceutical during the first quarter worth approximately $35,000. Dubuque Bank & Trust Co. acquired a new stake in Takeda Pharmaceutical during the first quarter worth approximately $41,000. Dumont & Blake Investment Advisors LLC acquired a new stake in Takeda Pharmaceutical during the first quarter worth approximately $230,000. Neville Rodie & Shaw Inc. acquired a new stake in Takeda Pharmaceutical during the first quarter worth approximately $475,000. Finally, Contravisory Investment Management Inc. acquired a new position in shares of Takeda Pharmaceutical in the 1st quarter valued at $28,000. Institutional investors own 11.45% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Get a free copy of the Zacks research report on Takeda Pharmaceutical (TAK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.